GLP-1 receptor agonists produced meaningful additional weight loss in bariatric surgery patients with suboptimal results or weight regain — tirzepatide led with 15.5% total weight loss, followed by semaglutide at 11.4% and liraglutide at 9.2%.
15.5% total weight lossTirzepatide achieved the highest weight loss among GLP-1 drugs for post-bariatric surgery patients, with semaglutide at 11.4% and liraglutide at 9.2% — all after at least 3 months of treatment
What the researchers found
Across 19 studies and 1,290 patients with suboptimal initial response or weight regain after bariatric surgery, GLP-1 receptor agonists produced the following results after at least 3 months:
• Tirzepatide: 15.50% total weight loss (TWL), 12.60 kg
• Semaglutide: 11.38% TWL, 11.62 kg
• Liraglutide: 9.24% TWL, 8.56 kg
Longer treatment duration improved outcomes: semaglutide at 12 months achieved 13.15% TWL and 14.68 kg loss, compared to 10.18% TWL and 9.43 kg at 6 months. Liraglutide showed similar time-dependent gains (10.80% TWL at ≥12 months vs 7.65% at ≤6 months).
Significant improvements were also seen in triglycerides, total cholesterol, LDL cholesterol, HbA1c, and ALT levels. Common adverse effects included nausea (23%), constipation (10%), fatigue (8%), vomiting (6%), diarrhea (6%), and headache (6%), with only 3% discontinuing due to side effects.
Why it matters
Weight regain affects a significant proportion of bariatric surgery patients and has been a persistent clinical challenge with limited treatment options. This meta-analysis provides strong pooled evidence that GLP-1 receptor agonists — already established for primary obesity treatment — are also effective as a rescue strategy after surgery, potentially filling an important therapeutic gap.
How the study worked
Systematic review and meta-analysis with literature search across online databases. Nineteen studies including 1,290 bariatric surgery patients with suboptimal initial clinical response or weight gain recurrence were included. Primary outcomes were percentage total weight loss and absolute weight loss. Secondary outcomes included changes in biochemical markers (lipids, HbA1c, liver enzymes) and adverse effect rates. Results were stratified by drug type (liraglutide, semaglutide, tirzepatide) and treatment duration.
What this study cannot tell us
The 19 included studies were primarily observational and retrospective, lacking randomized controlled trial data. Heterogeneity across studies in surgical procedures, time since surgery, and treatment protocols may affect pooled estimates. Tirzepatide data were limited compared to liraglutide and semaglutide. Long-term outcomes beyond 12 months are poorly characterized. Publication bias cannot be excluded.
How to read the evidence
This is a systematic review and meta-analysis of 19 studies including 1,290 patients, representing a high level of evidence synthesis. However, the underlying studies were primarily observational rather than randomized controlled trials, which limits the overall evidence quality. The large pooled sample and consistent results across drugs strengthen confidence in the findings.
When this study was published
Published in 2025, this is a very current meta-analysis incorporating the latest data on GLP-1 agonists and tirzepatide in the post-bariatric surgery population. Findings are highly relevant to current clinical practice.
The bigger picture
This meta-analysis represents the convergence of two major obesity treatment modalities — bariatric surgery and GLP-1 peptide pharmacotherapy. Rather than competing approaches, the data suggest they can be complementary, with GLP-1 drugs rescuing patients whose surgical outcomes fall short. As newer dual and triple agonist peptides enter the market, the ceiling for post-surgical weight loss rescue is likely to rise further.
Questions still open
- Should GLP-1 agonists be routinely offered to bariatric surgery patients who show early signs of inadequate weight loss?
- How do the weight loss benefits compare to the costs of long-term GLP-1 therapy after surgery?
- Does weight regain return if GLP-1 agonists are discontinued in post-bariatric patients?
Common questions
Can GLP-1 drugs help if bariatric surgery didn't work well enough?
What side effects should post-bariatric patients expect from GLP-1 drugs?
Read the original research
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.
Obesity surgery, 35(3), 808-822
Citation
Nie, Yuntao; Zhang, Yiran; Liu, Baoyin; Meng, Hua. (2025). Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.. Obesity surgery, 35(3), 808-822. https://doi.org/10.1007/s11695-025-07733-8